ReviewJournal of Huntington's disease2020
Irritability in Huntington's Disease.
Review in Journal of Huntington's disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Assessing the efficacy of dextromethorphan/quinidine in treating irritability in Huntington's disease.Journal of Huntington's disease · 2026Trial
- Molecular basis of antagonism of the dimeric human arginine vasopressin receptor 1A.Nature communications · 2026Article
- Characterization of psychiatric admissions in Huntington disease: A retrospective review.Journal of psychosomatic research · 2025Article
- Pathomechanisms of behavioral abnormalities in Huntington disease: an update.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- [Psychiatric symptoms of Huntington's disease].Der Nervenarzt · 2024Review
- Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy.Alzheimer's research & therapy · 2024Article
- Irritability in stroke: a protocol for a prospective study.Frontiers in neurology · 2024Article
- Review
- Irritability and risk of lung cancer: a Mendelian randomization and mediation analysis.Journal of cancer research and clinical oncology · 2023Article
- Development and Psychometric Properties of a New Brief, Yet Comprehensive, Behavioral Questionnaire for Huntington's Disease.Movement disorders clinical practice · 2023Article
- Using a Clinical Formulation to Understand Psychological Distress in People Affected by Huntington's Disease: A Descriptive, Evidence-Based Model.Journal of personalized medicine · 2022Article
- Excessive response to provocation rather than disinhibition mediates irritable behaviour in Huntington's disease.Frontiers in neuroscience · 2022Article
- Converging evidence in support of omega-3 polyunsaturated fatty acids as a potential therapy for Huntington's disease symptoms.Reviews in the neurosciences · 2021Review
- Novel Substituted Heteroaryl Compounds for Treating Huntington's Disease.ACS medicinal chemistry letters · 2021Article
- Novel Substituted Heterocyclic and Heteroaryl Compounds for Treating Huntington's Disease.ACS medicinal chemistry letters · 2021Article
- Novel Substituted Benzothiazole Compounds for Treating Huntington's Disease.ACS medicinal chemistry letters · 2021Article
- Novel Substituted Monocyclic Heteroaryl Compounds for Treating Huntington's Disease.ACS medicinal chemistry letters · 2021Article
- Novel Heteroaryl Compounds for Treating Huntington's Disease.ACS medicinal chemistry letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a heritable and fatal neurodegenerative disease characterized by a triad of motor, cognitive and neuropsychiatric symptoms. A common and particularly detrimental neuropsychiatric alteration in HD gene carriers is irritability, which frequently manifests as abrupt and unpredictable outbursts of anger. This symptom increases the burden of HD in multiple ways, such as jeopardizing employment and straining familial or caregiver support. Although irritability in HD is diagnosed by the administration of standardized rating scales and clinical expertise, measurement of severity and progression is complicated by several factors. Currently, individuals with HD who present with irritability may be managed with a variety of psychotropic medications, primarily antidepressants and antipsychotics. While these therapies offer relief to individuals suffering from irritability in HD, they are often not sufficient. Here, we review irritability in the context of HD and emphasize the need for treatments that are better tailored to mitigate this troublesome symptom. An expeditious strategy in pursuit of this goal involves evaluating the efficacy of approved medications that are used to treat similar neuropsychiatric symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.